Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Bone Biomarker Identified for Metastatic Prostate Cancer

TON - MARCH 2012 VOL 5, NO 2 published on April 10, 2012 in In the News
Alice Goodman

A new quantitative imaging bone biomarker has been identified that can assess response and is prognostic for survival in men with metastatic castration-resistant prostate cancer (mCRPC). 

Called the bone scintigraphy index (BSI), it represents the first quantitative imaging biomarker in prostate cancer. In a head-to-head comparison, the BSI was superior to PSA (prostate-specific antigen)—the traditional method—in assessing response to therapy and prognosticating for survival after 3 and 6 months on therapy for mCRPC, according to a study published online ahead of print in the Journal of Clinical Oncology on January 9, 2012. Michael Morris, MD, Memorial Sloan-Kettering Cancer Center, New York City, was senior author of the paper.

Bone scintigraphy is an older technology that images bone but not the cancerous lesions themselves. It shows the effect on the bone surrounding the metastasis, and, as such, is considered an imperfect tool on its own. 

BSI is a method of expressing the tumor burden in bone as a percent of the total skeletal mass based on reference man skeletal masses. The study included 88 men enrolled in 4 different clinical trials who had bone scintigraphy done at baseline, 3 months, and 6 months on therapy

The percent change in BSI from baseline to 3 and 6 months was prognostic for survival. Doubling of the BSI was associated with an almost 2-fold increase in risk of death. When compared head-to-head with PSA, change in PSA from baseline was not prognostic for survival.

“BSI tells us about response to therapy and survival. When the BSI goes up, survival is shorter, and when it goes down, survival will be longer,” Morris explained. He and his colleagues are developing a computer-generated BSI that will have wide applicability. At present, the BSI is computed manually. 

Related Items
CMS Expands Access to Telehealth Benefits During COVID-19 Outbreak
Web Exclusives published on March 18, 2020 in Health Policy, In the News
FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib
Web Exclusives published on February 4, 2020 in FDA Updates, In the News, Lung Cancer, Thyroid Cancer
Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma
Web Exclusives published on January 28, 2020 in FDA Updates, In the News, Sarcoma
Mixed Findings in Annual Cancer Statistics Report
Web Exclusives published on January 20, 2020 in In the News
FDA Grants Approval to Avapritinib for Patients with GIST
Web Exclusives published on January 13, 2020 in FDA Updates, Gastrointestinal Cancers, In the News, Rare Cancers
Recap of FDA Drug Approvals in 2019
Web Exclusives published on January 7, 2020 in FDA Updates, In the News
FDA Will Require Early Assessment of New Targeted Agents That May Be Used in Pediatric Cancers
Web Exclusives published on December 16, 2019 in In the News, Pediatric Cancer
Regenerative Medicine Advanced Therapy Designation Granted to ADP-A2M4 for Synovial Sarcoma
Web Exclusives published on December 11, 2019 in FDA Updates, In the News, Sarcoma
FDA Approves Adakveo to Reduce Vaso-Occlusive Crises in Patients with Sickle-Cell Disease
Web Exclusives published on November 25, 2019 in FDA Updates, In the News
November 25, 2019 – Oncology News & Updates
Web Exclusives published on November 25, 2019 in FDA Updates, In the News, Leukemia, Lung Cancer, Lymphoma
Last modified: September 9, 2019